Management Forum courses now available at IPI Academy - visit IPI for an updated experience and a broader selection of courses and subjects
  • Home
  • Working Through Veterinary Drug Development in the EU and USA

Working Through Veterinary Drug Development in the EU (European Union) and USA Training Course

This practical five-day course provides a comprehensive understanding of veterinary medicine development in the EU and USA.

20-24 Jun 2022

& 5-9 Dec 2022

Book now


Course overview

This intensive five-day course provides a thorough understanding of how to develop a veterinary medicine in the EU and USA.

The development of a veterinary medicine is complex, time consuming and expensive. It requires teamwork from individuals with different scientific training and a wide range of skills. Everyone involved must be aware of the main stages in the development programme and be able to relate his or her responsibilities to the expertise and needs of the scientists and commercial members of the team. Furthermore, different approaches taken by the regulatory authorities in the EU and the USA mean that a comprehensive development programme must be designed in order for the product to be commercialised in both regions.

The event has been designed to demonstrate how pharmaceutical, pharmacological, toxicological and clinical investigations and regulatory management are brought together in the development programme. It will take participants through all the stages in the development of a veterinary medicinal product for which a marketing authorisation is sought in the EU and the USA. Presentations will cover pharmaceutical and process development, toxicological, pharmacological, residues and environmental studies, safety risk assessments, clinical development, regulatory and marketing input and project management.

Gain a comprehensive understanding of the processes for the EU and USA, including:

  • EU and US regulatory frameworks, strategies and procedures n MRLs Parts A & B; MAA Parts IIIA & IIIB
  • US FDA approach to HFS studies
  • User safety risk assessment in the EU
  • Planning pre-clinical and clinical development
  • Environmental risk assessment Phases I and II n EU and US target animal safety
  • Minor use and minor species (MUMS)
  • Writing and managing regulatory submissions

Who should attend?

This course has been designed for anyone who has limited experience in only one of the disciplines in veterinary medicine development, such as pharmaceutical or analytical development, clinical trials, regulatory affairs or quality assurance. Anyone learning the role of project manager, as well as more experienced personnel seeking to review special problems encountered in product development, will benefit from the comprehensive programme delivered by experienced professionals.

Previous delegates who have benefited from this course include clinical scientists, pharmaceutical scientists, marketing managers and personnel from regulatory affairs, R&D and development.


Day 1 09:00 - 15:00 UK/London

EU regulatory framework for regulation of veterinary medicines

  • What is the EU?
  • EU legal framework for regulation of veterinary medicines
  • Legal base of procedures and data requirements

US regulatory framework for regulation of veterinary drugs

  • Current governing laws and regulations
  • Federal agency jurisdictions

EU and USA: differences and similarities

  • INAD and NAD in USA
  • Phased submission in USA vs marketing authorisation application in EU
  • EU MRLs vs US HFS section
  • EU renewal, variations, extensions vs US supplements
  • EU certificate of suitability and EDMFs vs US DMFs
  • Different requirements for user safety and environmental risk assessments

The global development programmes

  • Requirements for EU
  • Requirements for USA
  • Achieving a global development programme

USA regulatory strategies and procedures

  • Applications for NCEs and supplements
  • Generic drug applications

EU regulatory strategies and procedures

  • Full and abbreviated applications
  • Generic applications
  • Centralised procedure
  • Decentralised, MRP and national procedures

Day 2 09:00 - 15:15 UK/London

MRLs Part A safety and MAA Part IIIA

  • The toxicological data requirements
  • Determining the NOEL and ADI

USA FDA approach to HFS studies

  • Toxicology studies
  • Margins of safety

MRLs Part B residues and MAA Part IIIB

  • ‘Hot’ and ‘cold’ residue studies
  • How to determine maximum residue limits
  • Analytical methods for residues
  • Determining the withdrawal period

FDA evaluation of consumer safety

  • Human food technical safety section
  • Residue issues

Workshop - session 1

Day 3 09:00 - 14:45 UK/London

Environmental risk assessment Phases I and II

  • Critical evaluation of your data package
  • Phase I assessment
  • Refining risk assessment
  • Phase II assessment Tiers A and B
  • What to do if risk assessment gives cause for concern

User safety risk assessment in the EU

  • Reviewing toxicology studies
  • Setting the scenario
  • Risk assessment and management

Pharmacokinetics and bioequivalence

  • ADME studies
  • Bioequivalence

Workshop - session 2

Day 4 09:00 - 14:45 UK/London

EU and US clinical development

  • Dose selection
  • Field studies
  • VICH guidelines
  • Claim-driven approach in US
  • Protocol review and concurrence with CVM
  • Value of VICH guidance

EU and US target animal safety

  • Pivotal target animal safety studies
  • Filed safety studies
  • New VICH guideline on TAS

Minor use and minor species (MUMS)

  • MUMS approaches in EU and USA
  • What are minor uses?
  • What are minor species?
  • Approaches to preparation of clinical data

Workshop - session 3

Day 5 09:00 - 14:45 UK/London

Workshop - presentations

Pharmaceutical development and the CMC package

  • Characterising the active substance
  • Formulation development
  • Analytical development and setting specifications
  • Process scale-up and validation
  • Stability studies and shelf life

Managing the USA regulatory submission

  • Systems of review at CVM
  • Team interaction
  • Company and regulator interactions

Writing and managing the EU regulatory submission

  • Writing the marketing authorisation application
  • Summary of product characteristics and labelling
  • Working with writers on detailed and critical summaries in the EU
  • Pre-submission advice and oral hearings


Julian Braidwood (More...)

Julian Braidwood qualified as a Veterinary Surgeon and worked in mixed practices before spending fifteen years in R&D and Regulatory departments of five leading Animal Health companies. Julian has managed clinical trials and regulatory groups, experimental facilities, laboratories, and worked internationally in many countries. Having become an R&D Director within the industry, he co-founded Triveritas in 2,000 which grew rapidly internationally and became part of knoell in 2021. knoell is one of the leading service providers for worldwide registration and regulatory compliance in crop protection, crop nutrition, chemicals, cosmetics, animal health products, and medical devices. The knoell Group employs almost 600 people worldwide in more than 14 countries.

knoell is the only knowledge-based animal health consultancy and clinical studies specialist with its own technical staff based on three continents: North America, Europe, and Asia. The animal health team offers a full portfolio of services, including start-to-finish product development and ad hoc services – in all domesticated species for pharmaceuticals and biologicals, feed additives, novel, generic and borderline products.

David Petrick (More...)

Dr David Petrick has over 30 years’ experience in bringing novel animal health products to the marketplace. During his professional career he has worked in Regulatory Affairs and Product Development for both American Cyanamid Company and Schering-Plough Animal Health.
In 2004 he founded the Delta Consortium Regulatory Consulting Limited, serving as a consultant in Regulatory Affairs for animal health companies. In 2009 he joined Triveritas and was a part of the opening of Triveritas, USA. In 2004 Dr Petrick joined Velcera, a venture capital funded animal health company and was the Executive Vice President of Research Development and Regulatory Affairs. Velcera was sold to a major pharmaceutical company in 2010.
He holds a degree in veterinary medicine from the University of Pennsylvania, and a law degree from Seton Hall University. He is a member of the American Veterinary Medical Association, the American Bar Association, the New Jersey Bar Association and the New Jersey Bar.

Book now

Book now

20-24 Jun 2022
Live webinar
20-24 Jun 2022
Live webinar
GBP 1,999 1,499
EUR 2,799 2,099
USD 3,118 2,338
Until 16 May 22*
Enrol now
to attend
Live webinar
5-9 Dec 2022
Live webinar
5-9 Dec 2022
Live webinar
GBP 1,999 1,499
EUR 2,799 2,099
USD 3,118 2,338
Until 31 Oct 22*
Online registration unavailable: this date is nearing full capacity; please contact us to register.

Learn more about our face-to-face and webinar training formats.

* Note the early booking discount cannot be combined with any other offers or promotional code

Continuing professional development

This course qualifies for 24 hours for your CPD records.
More about CPD

Customised in-house training

We can customise this course to meet the requirements of your organisation and deliver it at your location and/or online.

Contact us

You may also be interested in

Previous customers include...

  • Bayer Animal Health GmbH
  • Bela-Pharm GmbH & Co. KG
  • Benchmark Animal Health Ltd
  • BI Vetmedica GmbH
  • Boehringer Ingelheim Pharma GmbH & Co KG
  • Boehringer Ingelheim RCV GmbH & Co KG
  • Boehringer Ingelheim Vetmedica - Inc. BIVI
  • Boehringer-Ingelheim Danmark A/S
  • Brouwer S.A.
  • Dechra
  • Dechra Development
  • Eco Animal Health Ltd
  • Elanco
  • GAB Consulting GmbH
  • IFAH - Europe
  • Indevp Education and Technology (Shanghai) Co. Ltd.
  • Merial
  • Merial SAS
  • MSD Animal Health Innovation GmbH
  • National Drug Authority
  • Novartis Animal Health Inc
  • Novartis Animal Health UK Ltd
  • Novartis Animal Health US Inc
  • Novus Spain SA
  • Orion Corporation
  • Pharmaq AS
  • Sumitomo Chemical
  • Sumitomo Chemical Co Ltd.
  • TriviumVet

The webinar was prepared in a high quality manner.

Michel Salatiel Guzman Gomez, Boehringer Ingelheim Vetmedica GmbH, Jun 21

David and Julian explained the overall process clearly and concisely, highlighting challenges and proposing solutions to encourage smooth transitions throughout the development process and registration in the EU and US. The course was very interactive and I enjoyed the case study – working through the development process with other industry colleagues, and listening to their approaches for their cases. It was great to have resources easily accessible, and the expertise of [the speakers] to allow for open discussions.

Abigail Harwood, Regional Pharmacovigilance Coordinator, Bayer, Jun 19

Both [the speakers] did a really good Job

Daniel Kulke, Head of Laboratory, Bayer Animal Health GmbH, Jun 19

Clear, concise content. Very knowledgeable speakers that we open to questions and discussion throughout the course.

Gemma Kennedy, Head of Regulatory & Quality, TriviumVet, Jun 19

An excellent comprehensive course that helps bridge both the EU and USA regulatory realities. Very professional and competent speakers. Masterclass level, definitely a must for those starting in project development!

Adrienne Frasco Schellauf, Regulatory Affairs Senior Associate, Zoetis , Jun 19

Speakers were very knowledgable on the subject matter.

Rondeep Bhui, Director, Global Pharmacovigilance, Elanco Animal Health, Jun 19

Extremely professional, could not find better qualified speakers. Definitely a masterclass

Ludovic Pelligand, Associate Professor in Clinical Pharmacology and Anaesthesia, Royal Veterinary College, Jun 17

The course was put together very well in its entirety - location, accommodations, course length and content, speakers

Jean Dory, Manager, Dechra Development, Jun 17

Really good, I would recommend it

Daniel Rodes, Merial SAS, Jun 17

Excellent - kept dry subject matter interesting and interactive. Well planned and excellent speakers with lots of real life experience

Melissa Coffman, Clinical Manager, Ceva Animal Health, Jun 17

Overall it was very good course

Pinalee Nanda, Regulatory Affairs Specialist, Bayer New Zealand Ltd, Jun 17

Very good, easy to understand

Naomi Isaka, Live Stock Clinical Development Manager, CEVA Sante Animale, Jun 16

Very interesting course, enriching, speakers know a lot what they are talking about and can answer all questions. Really good!

Marine Porri, Project Formulation Manager, Ceva Sante Animale Sa, Jun 16

The course was really good content. All the speakers had vast knowledge on the subjects and were happy to answer any questions.

Susan Scanlan, Regulatory Affairs Manager, Dechra Ltd, Jun 16

Very interesting course, enriching, speakers know a lot what they are talking about and can answer all questions. Really good!

Marine Porri, Project Formulation Manager, Ceva Sante Animale Sa, Jun 16